ホーム>>Signaling Pathways>> Others>>TCV-309 chloride

TCV-309 chloride

カタログ番号GC33088

TCV-309 クロリドは、強力で特異的な血小板活性化因子 (PAF) 拮抗薬です。 TCV-309 クロリドは、ウサギおよびヒトの血小板の PAF 誘導凝集、およびウサギ血小板ミクロソームへの [3H]PAF 結合を、それぞれ 33 nM、58 nM、および 27 nM の IC50 値で特異的に阻害します。 TCV-309クロリドはアナフィラキシーショックに有益な効果があります。

Products are for research use only. Not for human use. We do not sell to patients.

TCV-309 chloride 化学構造

Cas No.: 121494-09-5

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$349.00
在庫あり
1mg
$108.00
在庫あり
5mg
$252.00
在庫あり
10mg
$396.00
在庫あり
50mg
$1,080.00
在庫あり
100mg
$1,512.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

TCV-309 chloride is a platelet activating factor (PAF) antagonist. (1) TCV-309 chloride specifically inhibited PAF-induced aggregation of rabbit and human platelets. (2) TCV-309 chloride selectively inhibited the PAF-induced hypotension, hemoconcentration and death with ED50 values of 2.7, 6.4 and 1.7 micrograms/kg (i.v.), respectively. TCV-309 (chloride) most potently protected mice from death induced by PAF and due to anaphylactic shock with ED50 values of 2.1 and 2.6 micrograms/kg (i.v.), respectively. (3) TCV-309 chloride also reversed PAF-induced hypotension and endotoxin-induced hypotension in rats with ED50 values of 3.3 and 1.2 micrograms/kg (i.v.), respectively.

[1]. Terashita Z et al. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther. 1992 Feb;260(2):748-55.

レビュー

Review for TCV-309 chloride

Average Rating: 5 ★★★★★ (Based on Reviews and 10 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TCV-309 chloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.